Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab with or without Dacarbazine in Metastatic Melanoma
NCT00533702Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2007
- Primary completion
- May 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ramucirumab in melanoma, sponsored by Eli Lilly and Company. Started Nov 2007; status: completed.
02
Drugs
ramucirumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00533702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00533702.